These are additional notices applicable to this website.
A combination-therapy that has the potential to overcome and/or prevent the commonly observed acquisition of sorafenib resistance, which is associated with treatment failure in patients with hepatocellular carcinoma.
An efficient delivery vehicle for therapeutic oligonucleotides with high efficiency.
Self-assembling, highly stable RNA cages amenable to custom functionalization and cargo delivery
Parthenolide analogues derived from plants could be effective in treating leukemia or supplementing other treatments.
Nucleolin (NCL) is up-regulated in cancer cells, and modulates pro-tumorigenic pathways and chemoresistance. This anti-NCL agent binds and blocks NCL signaling, and may be optimized as cancer therapeutic and diagnostic tool.